Últimas noticias sobre Silence Therapeutics (NASDAQ:SLN) Bolsa

Silence Therapeutics

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

MODV

OLMA

Descubre las principales acciones sobrevendidas del sector sanitario con RSI bajo 30, incluyendo SLN, MODV y OLMA.

Las acciones más sobrevendidas del sector sanitario con RSI bajo 30

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics PLC

SELINA HOSPITALITY PLC HS

SELINA HOSPITALITY PLC by Selina Hospitality PLC

Selina Hospitality PLC

SILENCE THERAPEUTICS ORD by Silence Therapeutics, Plc.

Southland Holdings Inc

SOLUTION FINL INC by Solution Financial Inc.

Solution Financial Inc

Stabilis Solutions Inc

Soluna Holdings Inc

Soluna Holdings, Inc. - 9.0% Series A Cumulative Perpetual Preferred Stock

STELLA INTL HLDGS LTD ORD by Stella International Holdings Ltd.

Stella International Holdings Ltd

STELLA INTL HLDG UNSP/ADR by Stella International Holdings Ltd.

SALON MEDIA GROUP INC by Salon Media Group, Inc.

Salon Media Group Inc

Soleno Therapeutics Inc

SOLUTIONS 30 SE UNSP/ADR by Solutions 30 S.E.

Solutions 30 SE

Selina Hospitality PLC Warrants (27/10/2027)

SOLANBRIDGE GROUP INC by Solanbridge Group, Inc.

Solanbridge Group Inc

TCW Senior Loan ETF

Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) has outperformed the market over the past 15 years by 15.64% on an annualized basis producing an average annual return of 27.78%. Currently, Amazon.com has a market capitalization of $2.47 trillion. 
Buying $100 In AMZN: If an investor had bought $100 of AMZN stock 15 years ago, it would be worth $3,745.32 today based on a price of $234.56 for AMZN at the time of writing.
<h3>Amazon.com's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737762309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

$100 Invested In Amazon.com 15 Years Ago Would Be Worth This Much Today

Philadelphia Eagles wide receiver A.J. Brown, one of the highest-paid players in the NFL, has been making headlines lately – not just for his on-field talent but for his unassuming lifestyle choices. Brown, who signed a $96 million contract extension last offseason, surprised fans when he pulled up to a playoff game in a modest $30,000 Honda Accord.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">100 million dollar receiver AJ Brown is going viral for pulling up in a $30,000 Honda to todays game <a href="https://t.co/aqJPn6YPp7">pic.twitter.com/aqJPn6YPp7</a>
&mdash; SAY CHEESE! &#x1f444;&#x1f9c0; (@SaycheeseDGTL) <a href="https://twitter.com/SaycheeseDGTL/status/1881055447572271317?ref_src=twsrc%5Etfw">January 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>The Biggest Disruption To IP Since Disney — <a href="https://www.benzinga.com/money/elf-labs-1">Get in now as they monetize a $2 Trillion market by building content around the most profitable Character IP in history and combining it with the Patented Technology IP of the future.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
While luxury cars are often the norm for athletes of his caliber, Brown's decision sparked a wave of admiration on social media. Many praised him for staying grounded despite his wealth. One <a href="https://x.com/Talmadge18/status/1881084987363192934">tweet</a> by wealth manager Adam Talmadge summed up the sentiment: "This should be praised, not shamed! 78% of NFL players experience financial stress within two years of leaving the league. Warren Buffett drives a 2014 Cadillac XTS! I see a man who understands financial responsibility."
The comparison to billionaire investor Warren Buffett isn't far off. Buffett, famously frugal, <a href="https://www.benzinga.com/general/24/05/39040353/warren-buffett-drives-10-year-old-cadillac-bought-with-hail-damage">still drives a 2014 Cadillac XTS</a> he purchased with hail damage and lives in the same modest Omaha home he <a href="https://www.benzinga.com/news/24/09/41107810/billionaire-warren-buffett-still-lives-in-an-old-corner-house-he-purchased-for-32k-i-couldnt-imagine">bought in 1958 for $31,500</a>. Like Buffett, Brown's choice reflects a financial discipline rare in professional sports.
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">A Viral Moment That Resonates</h2>
This isn't the first time Brown has gone viral during the NFL playoffs. In the Eagles' Wild Card win over the Green Bay Packers, cameras caught him reading a self-help book, Inner Excellence by Jim Murphy, on the sidelines. The moment resonated so much with fans that it <a href="https://www.benzinga.com/general/psychology/25/01/42964097/nfl-star-helps-self-help-book-hit-1-on-amazon-my-teammates-call-it-the-recipe">catapulted the book to #1</a> on Amazon's charts. Brown explained that the book, which focuses on mental toughness and peak performance, helps him stay sharp on and off the field.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">AJ Brown is reading a book on the sideline? &#x1f4da;&#x1f602; &#x1f4fa; FOX <a href="https://t.co/jQGv8smD9N">pic.twitter.com/jQGv8smD9N</a>
&mdash; FOX Sports: NFL (@NFLonFOX) <a href="https://twitter.com/NFLonFOX/status/1878597906321609099?ref_src=twsrc%5Etfw">January 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Brown's grounded approach to finances and mental health has won him admiration beyond football. In a league where players are often pressured to flaunt their wealth, his modest car and sideline reading habit symbolize his focus on long-term well-being.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Why It Matters</h2>
Brown's actions remind us that wealth doesn't have to result in flashy spending. Statistics show that many NFL players face financial difficulties shortly after retirement, highlighting the importance of financial literacy and responsibility. Brown sets an example for athletes and fans by choosing a reliable and affordable car.
Buffett has often said that additional spending doesn't significantly improve the quality of life after a certain level of comfort. Similarly, Brown's decisions – from his car to his mental game – demonstrate a commitment to living intentionally, even in a world where excess is often celebrated.
Read Next:
<ul>
<li>They're saying this is the biggest breakthrough in Next-Gen Tech since the iPhone. <a href="https://www.benzinga.com/money/elf-labs-1">There&#8217;s now a limited window for investors to claim shares at just $2/share with $980 minimum—but the clock is ticking.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

$100 Million Receiver AJ Brown Goes Viral Again. This Time For Arriving In A $30,000 Honda Drawing Warren Buffett Comparisons

Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) has outperformed the market over the past 15 years by 1.26% on an annualized basis producing an average annual return of 13.39%. Currently, Encompass Health has a market capitalization of $9.63 billion. 
Buying $1000 In EHC: If an investor had bought $1000 of EHC stock 15 years ago, it would be worth $6,679.64 today based on a price of $95.66 for EHC at the time of writing.
<h3>Encompass Health's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737761410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Encompass Health 15 Years Ago Would Be Worth Today

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has outperformed the market over the past 20 years by 1.53% on an annualized basis producing an average annual return of 10.03%. Currently, Nike has a market capitalization of $109.48 billion. 
Buying $100 In NKE: If an investor had bought $100 of NKE stock 20 years ago, it would be worth $679.40 today based on a price of $73.55 for NKE at the time of writing.
<h3>Nike's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737760520_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Nike 20 Years Ago Would Be Worth Today

LGTY

Trading Halt: Halt status updated at 6:15:00 PM ET: Quotation Resumption: News and Resumption Times

United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) has outperformed the market over the past 15 years by 2.96% on an annualized basis producing an average annual return of 15.09%. Currently, United Airlines Holdings has a market capitalization of $34.55 billion. 
Buying $1000 In UAL: If an investor had bought $1000 of UAL stock 15 years ago, it would be worth $8,585.45 today based on a price of $105.05 for UAL at the time of writing.
<h3>United Airlines Holdings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737758709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning United Airlines Holdings Stock In The Last 15 Years

OpenAI on Thursday released a research preview of a new AI agent called &#8220;Operator,&#8221; which uses the internet <a href="https://www.benzinga.com/topic/artificial-intelligence">to perform a range of tasks</a>. 
Analysts are weighing in on which publicly traded companies could benefit <a href="https://www.benzinga.com/media/24/11/41964846/openais-operator-ai-agent-will-perform-tasks-like-coding-travel-booking-and-more-launch-expected-in-january-next-year-report">from the collaboration</a>.
Expert Ideas: Bank of America Securities analysts, led by Michael McGovern, highlighted Operator's capabilities. For example, it can:
<ul>
<li>Book rides from Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>)</li>
<li>Order from restaurants using DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) and</li>
<li>Add items to an order on Maplebear, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) Instacart platform. </li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43136971/will-soundhound-ai-stock-get-a-boost-from-project-stargate">Will SoundHound AI Stock Get A Boost From Project Stargate?&nbsp;</a>
BofA pointed to OpenAI's demonstration of Operator which shows the AI agent ordering food from Instacart using a recipe to add each ingredient to the shopping cart. The firm sees AI agents as especially helpful with "complex basket-building" of online grocery orders.&nbsp;
"In our view, grocery ordering online could become significantly easier with AI Agents, and expect DASH &amp; Uber would likely have the most relative benefit," the analysts wrote.&nbsp;&nbsp;
The collaborations with Uber, Instacart and DoorDash are in the early stages and BofA expects the possibility of long-term partnerships allowing for more streamlined and/or additional services offered. &nbsp;
OpenAI said that Operator employs a "Computer-Using Agent" model, which integrates GPT-4o's vision capabilities with advanced reasoning through reinforcement learning. This allows it to interact with graphical user interfaces (GUIs) without custom API integrations.
Operator is currently available to subscribers of OpenAI&#8217;s $200-per-month Pro tier in the U.S. and BofA expects expansion to subscribers on the $20-per-month tier later in 2025.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Travel

Analyst Ratings

Tech

General

CART

DASH

UBER

OpenAI's AI Agent Operator Could Boost Instacart, Uber, DoorDash: Analyst

Trading Halt: Halted at 5:35:47 p.m. ET - Trading Halt: Halt News Pending

On January 23, 2025, HWH International Received A Notice From The Nasdaq Stock Market, Informing The Company That It Has Demonstrated Compliance With Nasdaq's Listing Rule 5550(b)(1)

Offerings

Power REIT Files For Mixed Shelf Of Up To $50M

Source Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOR#NYSE">SOR</a>), a closed-end fund ("Source"), is interested in discussing a potential merger with 180 Degree Capital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TURN#NASDAQ">TURN</a>) ("TURN"). First Pacific Advisors, LP ("FPA"), is the adviser to Source and is a registered investment adviser. FPA currently manages $27 billion, which includes $350 million1 related to its management of Source. FPA has a long history of investment excellence - of the 150 largest mutual fund families in the United States, Morningstar recently ranked FPA #2 in terms of "Average Morningstar Rating."2
We propose that TURN merge into Source in an all-stock transaction valuing TURN at 101% of net asset value per share ("NAV").3

TURN

Source Capital Proposes Merger With 180 Degree Capital Corp; Proposes That TURN Merge Into Source In An All-Stock Transaction Valuing Turn At 101% Of Net Asset Value Per Share

Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) has outperformed the market over the past 5 years by 16.87% on an annualized basis producing an average annual return of 30.08%. Currently, Kinsale Cap Gr has a market capitalization of $10.08 billion. 
Buying $1000 In KNSL: If an investor had bought $1000 of KNSL stock 5 years ago, it would be worth $3,840.57 today based on a price of $432.64 for KNSL at the time of writing.
<h3>Kinsale Cap Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737757814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KNSL

Here's How Much $1000 Invested In Kinsale Cap Gr 5 Years Ago Would Be Worth Today

On January 21, 2025, Solid Power Operating, Inc., a wholly owned subsidiary of Solid Power, Inc. (collectively, the "Company"), and the United States Department of Energy (the "DOE") entered into an Assistance Agreement (the "Assistance Agreement"), with an effective date of January 1, 2025. The Assistance Agreement provides that the DOE will provide the Company with funding of up to $50 million for the Company's installation of equipment necessary for the continuous production of sulfide-based solid electrolyte material. The Company's cost share obligation under the Assistance Agreement is $60 million. The Company is subject to certain reporting requirements and compliance obligations under the Assistance Agreement, as set forth in more detail in the Assistance Agreement.

Contracts

SLDP

Solid Power And DOE Announced $50M Assistance Agreement For Production Of Sulfide-Based Solid Electrolyte Material, With Company Cost Share Of $60M

JTAI

Jet.AI Files For Offering Resale Of Up To 1.27M Shares Of Common Stock By The Selling Stockholder

IMVT

Immunovant Selling Stockholders To Offer Up To 5.7M Shares Of Common Stock

KULR

KULR Technology Group Increases Maximum Aggregate Offering Amount Under At The Market Offering Agreement To $100M

Buybacks

AEYE

AudioEye Approves $12.5M Stock Repurchase Program

SYRA

Syra Health Files For Mixed Shelf Of Up To $75M

MVST

Microvast Holdings Files For Mixed Shelf Offering Of Up To $250M

Management

CTCX

Carmell's Kendra Bracken-Ferguson Departs As CEO; Rajiv Shukla Appointed As New CEO

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report), with a p...

Silence Therapeutics' Promising Phase 2 Results and Growth Potential Drive Buy Rating

BMO Capital notes that Silence Therapeutics (SLN) is trading significantly lower following AHA updates due to concerns that favorable data from ora...

Silence Therapeutics weakness after AHA updates 'overdone,' says BMO Capital

Silence Therapeutics (SLN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris...

Silence Therapeutics: Anticipated Zerlasiran Partnership and Favorable Pelacarsen CVOT Outlook Drive Buy Rating

Silence Therapeutics (SLN) has released an update. Silence Therapeutics has unveiled promising Phase 1 data for their siRNA therapy, divesiran, sho...

Silence Therapeutics Advances Promising siRNA Therapy for PV

Silence Therapeutics (SLN) announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TM...

Silence Therapeutics announces additional results from SANRECO study

Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Silence Therapeutics (SLN – Research Report), retaining the price target of $49.00...

Promising Prospects for Silence Therapeutics: Buy Rating Justified by Positive Phase 1 Data and Safety Profile

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stoke Therapeutics (STOK – Research Report) and Sile...

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Silence Therapeutics (SLN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crispr Therapeutics AG (CRSP – Research Report), Sil...

Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)

Silence Therapeutics ( ($SLN) ) has shared an announcement. Silence Therapeutics will transition to filing reports as a U.S. domestic issuer starti...

Silence Therapeutics to Transition to U.S. Issuer Status

Silence Therapeutics: Simply No Match For Its Orally Dosed Rival (Downgrade)

CRSP

STOK

Press Releases

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Silence Therapeutics

Noticias

Últimas noticias sobre Silence Therapeutics (NASDAQ:SLN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL